Jiménez-Jiménez F J, López-Alvarez J, Sánchez-Chapado M, Montero E, Miquel J, Sierra A, Gutiérrez F
Department of Neurology, Hospital Príncipe de Asturias, Alcalá de Henares (Madrid), Spain.
Clin Neuropharmacol. 1995 Jun;18(3):277-9. doi: 10.1097/00002826-199506000-00009.
We describe a 68-year-old patient with Parkinson's disease who developed retroperitoneal fibrosis during pergolide treatment. Because pergolide is an ergot derivative, it could be related to the development of this complication.